![]() ![]() Symptoms appeared about a week or two after receiving the J&J vaccine. Most instances of TTS occurred in female adults between the ages of 18 and 48 years. The medical term for this condition is thrombosis with thrombocytopenia syndrome (TTS). These blood clots were found in the large blood vessels of the brain or other parts of the body and were associated with a low platelet count. This pause was so instances of rare but serious blood clots could be further investigated. On April 13, 2021, the FDA and the CDC recommended a pause on J&J vaccinations. The CDC currently doesn’t recommend the use of one vaccine over another. The FDA notes that the only way to directly compare the efficacy of the three vaccines is to conduct a head-to-head clinical trial. were carried out at different points in the pandemic.included various pools of people across many geographic locations.However, it’s important to note that it’s not possible to make direct comparisons between the three COVID-19 vaccines. These numbers may seem much higher than those of the J&J vaccine. Clinical trial data of the Moderna vaccine reported an efficacy of 94.1 percent 14 days after the second dose. These are the mRNA vaccines produced by Pfizer and Moderna.ĭata from clinical trials of the Pfizer vaccine found an efficacy of 95 percent 7 days after the second dose. You may be wondering how the efficacy of the J&J vaccine stacks up against the other two COVID-19 vaccines authorized for use in the United States. How does the Johnson & Johnson vaccine’s efficacy compare with Moderna’s and Pfizer’s? In fact, the J&J vaccine was 93 percent effective at preventing hospitalization for COVID-19 14 days after vaccination and 100 percent effective 28 days after. J&J vaccine efficacy for severe to critical COVID-19 14 days after vaccination was:Īdditionally, individuals receiving the J&J vaccine were less likely to be hospitalized than those who didn’t receive the vaccine. The World Health Organization (WHO) estimates that 20 percent of people with COVID-19 experience a severe to critical illness that often requires hospitalization. J&J vaccine’s efficacy for mild to moderate COVID-19 14 days after vaccination was: Many individuals can recover from mild to moderate COVID-19 at home. In most people, COVID-19 is a mild or moderate illness. The results from this clinical trial found that the J&J vaccine could protect against mild to moderate and severe to critical cases of COVID-19. The FDA reviewed this data, along with manufacturing information provided by Johnson & Johnson, when deciding to grant emergency use authorization. The efficacy of the J&J vaccine was tested in a clinical trial involving more than 40,000 people. How effective is the Johnson & Johnson vaccine? ![]()
0 Comments
Leave a Reply. |